These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38343204)

  • 21. Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia.
    Clothier HJ; Crawford N; Russell MA; Buttery JP
    Euro Surveill; 2017 May; 22(20):. PubMed ID: 28552101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan.
    Huang WT; Chen WW; Yang HW; Chen WC; Chao YN; Huang YW; Chuang JH; Kuo HS
    Vaccine; 2010 Oct; 28(44):7161-6. PubMed ID: 20804804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
    LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
    Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
    Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
    MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.
    Kim MS; Jung SY; Ahn JG; Park SJ; Shoenfeld Y; Kronbichler A; Koyanagi A; Dragioti E; Tizaoui K; Hong SH; Jacob L; Salem JE; Yon DK; Lee SW; Ogino S; Kim H; Kim JH; Excler JL; Marks F; Clemens JD; Eisenhut M; Barnett Y; Butler L; Ilie CP; Shin EC; Il Shin J; Smith L
    J Med Virol; 2022 Mar; 94(3):1085-1095. PubMed ID: 34709664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. System and facility readiness assessment for conducting active surveillance of adverse events following immunization in Addis Ababa, Ethiopia.
    Zeleke ED; Yimer G; Lisanework L; Chen RT; Huang WT; Wang SH; Bennett SD; Makonnen E
    Int Health; 2023 Nov; 15(6):676-683. PubMed ID: 36622733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Victorian Specialist Immunisation Services (VicSIS) - bolstering adult clinics for COVID-19 vaccines.
    Gordon SF; Virah Sawmy E; Duckworth E; Wolthuizen M; Clothier HJ; Chea M; Tenneti N; Blow N; Buttery JP; de Luca J; Korman TM; Barnes S; Slade C; Maggs C; Giles ML; Teh BW; Aboltins C; Langan KM; Van Diemen A; Crawford NW
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052701. PubMed ID: 35471988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lessons on causality assessment and communications from the 2019 South-East Asia Regional (SEAR) workshop on inter-country expert review of selected Adverse Events Following Immunization (AEFI) cases.
    MacDonald NE; Guichard S; Arora N; Menning L; Wilhelm E;
    Vaccine; 2020 Jul; 38(32):4924-4932. PubMed ID: 31611095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SAEFVIC: Surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018.
    Clothier HJ; Lawrie J; Lewis G; Russell M; Crawford NW; Buttery JP
    Commun Dis Intell (2018); 2020 Jun; 44():. PubMed ID: 32536336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From program suspension to the pandemic: A qualitative examination of Australia's vaccine pharmacovigilance system over 10 years.
    Phillips A; Carlson S; Danchin M; Beard F; Macartney K
    Vaccine; 2021 Sep; 39(40):5968-5981. PubMed ID: 34376308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring the safety of influenza A/H1N1 pandemic and seasonal vaccines in Morocco.
    Tebaa A; Benkirane R; Alj L; Cherkaoui I; Soulaymani-Bencheikh R
    Ther Adv Vaccines Immunother; 2022; 10():25151355221088157. PubMed ID: 35372783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015.
    Lei J; Balakrishnan MR; Gidudu JF; Zuber PLF
    Vaccine; 2018 Mar; 36(12):1577-1582. PubMed ID: 29454518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An evaluation of adverse events following an immunization campaign with the live, attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia.
    Hills SL; Soeung SC; Sarath S; Morn C; Dara C; Fischer M; Thigpen MC
    PLoS One; 2022; 17(6):e0269480. PubMed ID: 35679297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID-19 mRNA vaccination.
    Piché-Renaud PP; Morris SK; Top KA
    Br J Clin Pharmacol; 2023 Mar; 89(3):967-981. PubMed ID: 36480113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Landscape analysis of pharmacovigilance and related practices among 34 vaccine manufacturers' from emerging countries.
    Hartmann K; Pagliusi S; Precioso A
    Vaccine; 2020 Jul; 38(34):5490-5497. PubMed ID: 32591289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fever following immunization with influenza A (H1N1) vaccine in children: a survey-based study in the Netherlands.
    Broos N; van Puijenbroek EP; van Grootheest K
    Drug Saf; 2010 Dec; 33(12):1109-15. PubMed ID: 21077701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial.
    Gold MS; Lincoln G; Cashman P; Braunack-Mayer A; Stocks N
    Vaccine; 2021 Jan; 39(2):332-342. PubMed ID: 33279317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of death cases in Shenyang City, China, for immunization adverse event surveillance, 2009-2021.
    Gao D; Dong G; Zhu L; Jia N; Sun B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2263225. PubMed ID: 37782096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential immediate hypersensitivity reactions following immunization in preschool aged children in Victoria, Australia.
    Baxter CM; Clothier HJ; Perrett KP
    Hum Vaccin Immunother; 2018; 14(8):2088-2092. PubMed ID: 29624467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.